Across TCGA pan-cancer cohorts, MSANTD1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MSANTD1’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MSANTD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MSANTD1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.
LIHC, THCA, and KIRC are the cancer types where MSANTD1 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MSANTD1 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.